Optimizing Care for Patients With Tardive Dyskinesia

Release Date: February 12, 2025

Expiration Date: February 12, 2026

Activity Overview

A number of key domains (ie, social, physical, vocational, and psychological) relating to an individual’s life and function can be affected by tardive dyskinesia (TD), including social, physical, vocational, and psychological. Clinical recognition of the impacts of these domains is essential for clinicians to provide compassionate, patient-centered care, the initial part of which is a proper assessment, followed by selecting the best evidence-based therapy. Traditionally, no FDA-approved agents were available to treat TD, so using medications with a lower risk of TD and tapering medications at the first sign of TD symptoms was considered the best approach. However, the availability of vesicular monoamine transporter-2 (VMAT2) inhibitor therapy shifted the TD treatment paradigm. With this advance in therapy, clinicians whose scope of practice involves the care of patients with or at risk for TD require ongoing continuing education to hone and reinforce their clinical decision-making.

This educational activity is an archive of the live featured symposium held on January 17, 2025.

Target Audience

This educational activity is directed toward psychiatric nurse practitioners and psychiatric physician assistants. Advanced practice professionals on the front lines of care who treat psychiatric disorders in both outpatient and inpatient settings and other health care professionals interested in the treatment of psychiatric disorders are also invited to participate to further enhance knowledge of current psychiatric treatment options.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Assess clinical trial data for therapies for TD
• Incorporate therapies into individualized management plans for patients with TD

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.